Emmes today announced that it provided the data management support for a study, funded by the National Institutes of Health (NIH) and approved by the Food and Drug Administration (FDA), to safely use Acyclovir to treat infants infected with the Herpes Simplex Virus. Acyclovir, known by the brand name Zovirax, now includes recommended usage and dosage for newborns and infants up to three months of age on its label.
{iframe}https://www.prnewswire.com/news-releases/emmes-supported-study-results-in-the-first-pediatric-drug-labeling-change-for-2019-300820841.html{/iframe}